检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:许振坤[1] 姚朱华[2] 王佩显[3] 曹月娟[2] 李永斌[2]
机构地区:[1]天津医科大学研究生院,300070 [2]天津市人民医院心内科 [3]天津医科大学总医院心内科
出 处:《天津医药》2012年第6期560-562,共3页Tianjin Medical Journal
摘 要:目的:探讨氟伐他汀联合普罗布考对急性冠脉综合征(ACS)患者血脂及血清超敏C-反应蛋白(hs-CRP)水平的影响。方法:收集ACS住院患者60例,随机分为A、B、C3组,每组20例,A组给予氟伐他汀40mg,1次/晚;B组给予氟伐他汀80mg,1次/晚;C组给予氟伐他汀40mg,1次/晚,并加用普罗布考250mg,2次/d。3组患者均于治疗前清晨空腹取血,测定hs-CRP和血脂水平,包括总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)。结果:治疗前3组间各项血脂指标及hs-CRP水平差异均无统计学意义(P>0.05)。治疗后C组血脂指标和hs-CRP水平较A组均降低(P<0.05),TC及HDL-C水平较B组均低(P<0.05),而TG及LDL-C水平与B组比较差异无统计学意义(P>0.05)。治疗后B、C组中TC、TG、LDL-C水平较治疗前降低(P<0.05或P<0.01);各组hs-CRP水平治疗前后差异均有统计意义(P<0.05)。结论:氟伐他汀联合普罗布考或大剂量氟伐他汀均能明显降低ACS患者血脂及hs-CPR水平,尤以氟伐他汀联合普罗布考效果更为显著。Objective: To evaluate the effect of fluvastatin-probucol combined therapy on levels of serum lipid and se- rum high sensitivity C-reactive protein (hs-CRP) in patients with acute coronary syndrome (ACS). Methods: A total of 60 pa- tients with ACS were randomly divided into three groups, A, B and C groups(n=20 for each group). Patients of group A were taken fluvastatin 40 mg/d, patients of group B were taken fluvastatin 80 mg/d and patients of group C were taken fluvastatin 40 mg/d and 250 mg of probucol twice a day. The serum levels of total cholesterol (TC), triglyeeride (TG), low density lipopro- tein cholesterol (LDL-C), high density ]ipoprotein cholesterol (HDL-C) and hs-CRP were examined before treatment in three groups. Results: There were no significant differences in serum levels of lipid and hs-CRP before treatment in three groups (P 〉 0.05). After 3 months treatment, serum levels of lipid and hs-CRP were lower in group C than those of group A (P 〈 0.05), levels of TC and HDL-C were lower in group C than those of group B (P 〈 0.05). There were no significant differences in levels of TG and LDL-C between group C and group B (P 〉 0.05). Compared with the pretreatment values, levels of TC and TG/LDL-C were significantly decreased in group B and group C after 3 months therapy (P 〈 0.05 or P 〈 0.01). There was a significant difference in the level of hs-CRP before and after treatment in three groups (P 〈 0.05). Conclusion: Combined treatment by fluvastatin and probucol or single high-dose fluvastatin therapy can significantly reduce serum levels of lipid and hs-CRP in ACS patiants. The combined treatment of fluvastatin with probucol could further strengthen the efficacy.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.222